Rough times at the US FDA and translation headaches in the EU
This article was originally published in RAJ Devices
It's been a rough few months for the US Food and Drug Administration.
You may also be interested in...
The withdrawal of the EU filing for abicipar pegol will fuel speculation that Allergan parent AbbVie is indeed ditching the potential treatment for wet AMD. US regulators have already said they won't approve the drug.
There is speculation that it is the end of the road for abicipar pegol but Allergan has declined to say whether this is the case for the product that has been in development for wet AMD.